Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 11:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Chronic Hepatitis C Virus
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
53
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 50 more
Conditions
Infectious Disease
Interventions
Not listed
Lead sponsor
Midwestern University
Other
Eligibility
18 Years to 90 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Downers Grove, Illinois
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization, Child, Hospitalized
Interventions
Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Cooperstown, New York • New York, New York
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Acceptability of a Vaginal Microbicide

NCT00111943
Conditions
HIV Infections, Hepatitis B, Chronic
Interventions
1% tenofovir gel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2007
U.S. locations
2
States / cities
Birmingham, Alabama • The Bronx, New York
Completed No phase listed Observational Accepts healthy volunteers

Acceptability Study of Vaginal Films for HIV Prevention

NCT01231763
Conditions
HIV Infections, Anti-Infective Agents
Interventions
No intervention (not applicable)
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving Antimicrobial-Prescribing in Emergency Departments

NCT03349567
Conditions
Anti-Bacterial Agents, Respiratory Tract Infections
Interventions
Audit-and-feedback
Behavioral
Lead sponsor
Iowa City Veterans Affairs Medical Center
Federal
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Indianapolis, Indiana • Sioux Falls, South Dakota
Conditions
Clostridium Difficile Infection
Interventions
MGB-BP-3
Drug
Lead sponsor
MGB Biopharma Limited
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Miami, Florida • Orlando, Florida • Idaho Falls, Idaho + 5 more
Completed Phase 4 Interventional Results available

Probiotics to Promote Intestinal Health

NCT02046512
Conditions
Communicable Diseases, Infection, Anti-Infective Agents, Therapeutic Uses, Pharmacologic Actions
Interventions
Probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2, Aspergillosis Invasive
Interventions
Isavuconazonium Injection [Cresemba], Placebo
Drug
Lead sponsor
Jeffrey Jenks, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Orange, California • Sacramento, California • San Diego, California
Conditions
Chronic Hepatitis C Virus
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
647 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
52
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 49 more
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Chlorhexidine gluconate
Drug
Lead sponsor
Procter and Gamble
Industry
Eligibility
13 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Columbus, Ohio + 1 more
Conditions
COVID-19, SARS-CoV 2, Severe Acute Respiratory Syndrome Coronavirus 2, Virus Disease, Coronavirus Infections, Pharyngeal Diseases
Interventions
Oral-B Mouth Sore mouthwash, Crest Pro-Health Multi-Protection mouthwash, CloSYS Ultra Sensitive Rinse mouthwash, Distilled water, Listerine Zero Mouthwash Product
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Francisco, California
Conditions
Skin and Subcutaneous Tissue Bacterial Infections
Interventions
Delafloxacin, Vancomycin, Aztreonam, Placebo
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
Montgomery, Alabama • Anaheim, California • Chula Vista, California + 14 more
Conditions
Bacterial Infection, Anti-infective Agents, Breast Implantation
Interventions
Cefadroxil discontinued early, Cefadroxil until drain removal
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Stony Brook, New York
Conditions
Surgical Site Infections, Surgical Wound Infection, Infections, Anti-Infective Agents
Interventions
nasal antimicrobial photodisinfection therapy
Combination Product
Lead sponsor
Ondine Biomedical Inc.
Industry
Eligibility
18 Years and older
Enrollment
4,787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
Englewood, Colorado • Brandon, Florida • Largo, Florida + 9 more
Conditions
Complicated Skin and Skin Structure Infections
Interventions
JNJ-32729463, linezolid, JNJ-32729463 placebo, linezolid placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
27
States / cities
Anaheim, California • Buena Park, California • Chula Vista, California + 23 more
Conditions
Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions
Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more
Conditions
HIV Infections
Interventions
Levofloxacin
Drug
Lead sponsor
R W Johnson Pharmaceutical Research Institute
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Raritan, New Jersey
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug Concentration Analysis of Micafungin in Overweight, Obese, and Extremely Obese Volunteers

NCT01090141
Conditions
Obesity, Nutrition Disorders, Overweight
Interventions
Micafungin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Gonorrhea
Interventions
Delafloxacin, Ceftriaxone
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
15 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
25
States / cities
Birmingham, Alabama • Chula Vista, California • La Mesa, California + 21 more
Conditions
Hepatitis C
Interventions
Locteron (controlled-release interferon alpha 2b), pegylated IFNa2b
Other · Biological
Lead sponsor
Biolex Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Detroit, Michigan • Dallas, Texas • San Antonio, Texas + 2 more
Conditions
Sinusitis
Interventions
Amoxicillin-Potassium Clavulanate Combination, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
1 Year to 10 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Madison, Wisconsin
Conditions
Peri-Implantitis
Interventions
2.5 mg Chlorhexidine gluconate chip
Drug
Lead sponsor
Dexcel Pharma Technologies Ltd.
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan + 2 more